Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The TP53 Arg72Pro polymorphism predicts visual and neurodegenerative outcomes in retinal detachment

  • Galindo-Cabello, Nadia
  • Sobas-Abad, Eva M.
  • Lapresa, Rebeca
  • Agulla, Jesús
  • Almeida, Angeles
  • López, Antonio
  • Pastor-Pareja, José Carlos
  • Pastor-Idoate, Salvador
  • Usategui-Martín, Ricardo
Retinal detachment (RD) separates the retina from the retinal epithelium, causing photoreceptor apoptosis and irreversible vision loss. Even with successful surgical reattachment, complete visual recovery is not guaranteed. The TP53 Arg72Pro polymorphism, implicated in apoptosis, has emerged as a potential predictor of RD outcomes. We investigated the impact of the Arg72Pro polymorphism on retinal neurodegeneration and functional recovery in patients. The underlying mechanisms were analyzed in a humanized TP53 Arg72Pro RD mouse model. In a cohort of 180 patients, carriers of the Pro allele exhibited decreased apoptotic gene expression and improved visual recovery. Complementary findings in mice revealed that the Pro variant preserved photoreceptor integrity and reduced apoptosis rates following RD. Our findings highlight the potential of this TP53 polymorphism as a biomarker for RD outcomes and a tool for tailoring therapies. This study underscores the importance of integrating genetic profiling into personalized medicine approaches to improve recovery of RD patients’ visual outcomes., We express our gratitude to the patients for their participation, to the University of Valladolid’s Animal Welfare and Research Service for their care and technical support, and to the operating room nurses from both the University Clinic Hospital of Valladolid and the IOBA Eye Institute at the University of Valladolid for assisting in blood sample collection. This study was supported by MICIU/AEI (PID2020-114585RA-I00, PID2023-147958OB-I00, and PDC2023-145857-100 to S.P.I. and R.U.M.) (as appropriate, by the European Union Next Generation EU/PRTR) and the Instituto de Salud Carlos III (RD21/0002/0017 and RD24/0007/0008 to S.P.I., PI21/00727 and RD21/0006/0005 to A.A.). Programa estratégico IOBA from Junta de Castilla y León (Spain) (CLU-2023-1-04 to S.P.I and R.U.M)., Peer reviewed